levofloxacin has been researched along with doxazosin in 5 studies
| Studies (levofloxacin) | Trials (levofloxacin) | Recent Studies (post-2010) (levofloxacin) | Studies (doxazosin) | Trials (doxazosin) | Recent Studies (post-2010) (doxazosin) |
|---|---|---|---|---|---|
| 4,346 | 581 | 2,209 | 1,372 | 439 | 283 |
| Protein | Taxonomy | levofloxacin (IC50) | doxazosin (IC50) |
|---|---|---|---|
| 5-hydroxytryptamine receptor 4 | Cavia porcellus (domestic guinea pig) | 0.544 | |
| Interstitial collagenase | Homo sapiens (human) | 5.749 | |
| Beta-2 adrenergic receptor | Homo sapiens (human) | 2.748 | |
| Angiotensin-converting enzyme | Oryctolagus cuniculus (rabbit) | 2.2155 | |
| Alpha-1D adrenergic receptor | Homo sapiens (human) | 0.0034 | |
| 5-hydroxytryptamine receptor 2C | Homo sapiens (human) | 0.544 | |
| Sodium-dependent serotonin transporter | Homo sapiens (human) | 2.688 | |
| 5-hydroxytryptamine receptor 2B | Homo sapiens (human) | 0.368 | |
| Alpha-1A adrenergic receptor | Rattus norvegicus (Norway rat) | 0.0007 | |
| Sodium-dependent dopamine transporter | Homo sapiens (human) | 0.188 | |
| Potassium voltage-gated channel subfamily H member 2 | Homo sapiens (human) | 1.4022 | |
| Nuclear receptor subfamily 3 group C member 3 | Bos taurus (cattle) | 2.2155 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 4 (80.00) | 29.6817 |
| 2010's | 1 (20.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Benz, RD; Contrera, JF; Kruhlak, NL; Matthews, EJ; Weaver, JL | 1 |
| Andricopulo, AD; Moda, TL; Montanari, CA | 1 |
| Lombardo, F; Obach, RS; Waters, NJ | 1 |
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Jeong, CW; Jeong, H; Lee, SE; Lim, DJ; Son, H | 1 |
1 review(s) available for levofloxacin and doxazosin
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
1 trial(s) available for levofloxacin and doxazosin
| Article | Year |
|---|---|
Treatment for chronic prostatitis/chronic pelvic pain syndrome: levofloxacin, doxazosin and their combination.
Topics: Adrenergic alpha-Antagonists; Adult; Anti-Bacterial Agents; Doxazosin; Drug Therapy, Combination; Humans; Levofloxacin; Male; Middle Aged; Ofloxacin; Prospective Studies; Prostatitis | 2008 |
3 other study(ies) available for levofloxacin and doxazosin
| Article | Year |
|---|---|
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
Topics: Adverse Drug Reaction Reporting Systems; Artificial Intelligence; Computers; Databases, Factual; Drug Prescriptions; Drug-Related Side Effects and Adverse Reactions; Endpoint Determination; Models, Molecular; Quantitative Structure-Activity Relationship; Software; United States; United States Food and Drug Administration | 2004 |
Hologram QSAR model for the prediction of human oral bioavailability.
Topics: Administration, Oral; Biological Availability; Holography; Humans; Models, Biological; Models, Molecular; Molecular Structure; Pharmaceutical Preparations; Pharmacokinetics; Quantitative Structure-Activity Relationship | 2007 |
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Topics: Blood Proteins; Half-Life; Humans; Hydrogen Bonding; Infusions, Intravenous; Pharmacokinetics; Protein Binding | 2008 |